AI assistant
Sending…
Beam Therapeutics Inc. — Director's Dealing 2021
Jul 1, 2021
31533_dirs_2021-06-30_9ee872fc-cf18-4c47-9bbc-4d6774e0032f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2021-06-25
Reporting Person: Evans John M. (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-25 | Common Stock | L | 32 | $0.00 | Acquired | 1021461 | Direct |
| 2021-06-28 | Common Stock | L | 32 | $0.00 | Acquired | 1021493 | Direct |
| 2021-06-29 | Common Stock | J | 32 | $0.00 | Acquired | 1021525 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 223000 | Indirect |
Footnotes
F1: Distribution of BEAM common stock held by ARCH Venture Fund IX, L.P. to its partners for no consideration.
More from Beam Therapeutics Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Director's Dealing
2026
Feb 26
Annual Report
2026
Feb 24
Regulatory Filings
2026
Feb 24
Regulatory Filings
2026
Feb 12
Major Shareholding Notification
2026
Feb 5
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Feb 5
Major Shareholding Notification
2026
Feb 3